PMID- 28554261
OWN - NLM
STAT- MEDLINE
DCOM- 20180820
LR  - 20181202
IS  - 1366-5804 (Electronic)
IS  - 1354-750X (Linking)
VI  - 23
IP  - 2
DP  - 2018 Mar
TI  - Plasma alpha-1-acid glycoprotein as a potential predictive biomarker for 
      non-haematological adverse events of docetaxel in breast cancer patients.
PG  - 142-146
LID - 10.1080/1354750X.2017.1334152 [doi]
AB  - CONTEXT: Rash and oral mucositis are major non-haematological adverse events 
      (AEs) of docetaxel, in addition to fatigue, nausea, vomiting and diarrhoea, which 
      restrict the use of the drug in cancer therapy. Alpha-1-acid glycoprotein (AAG) 
      is an acute phase reactant glycoprotein and is a primary carrier of docetaxel in 
      the blood. Docetaxel has extensive binding (>98%) to plasma proteins such as AAG, 
      lipoproteins and albumin. OBJECTIVE: To study the association between plasma AAG 
      level and non-haematological AEs of docetaxel in Malaysian breast cancer patients 
      of three major ethnic groups (Malays, Chinese and Indians). MATERIALS AND 
      METHODS: One hundred and twenty Malaysian breast cancer patients receiving 
      docetaxel as single agent chemotherapy were investigated for AAG plasma level 
      using enzyme-linked immunosorbent assay technique. Toxicity assessment was 
      determined using Common Terminology Criteria of Adverse Events v4.0. The 
      association between AAG and toxicity were then established. RESULTS: There was 
      interethnic variation of plasma AAG level; it was 182 +/- 85 mg/dl in Chinese, 
      237 +/- 94 mg/dl in Malays and 240 +/- 83 mg/dl in Indians. It was found that low 
      plasma levels of AAG were significantly associated with oral mucositis and rash. 
      CONCLUSIONS: This study proposes plasma AAG as a potential predictive biomarker 
      of docetaxel non-haematological AEs namely oral mucositis and rash.
FAU - Jabir, Rafid Salim
AU  - Jabir RS
AD  - a Pharmacotherapeutics Unit, Department of Medicine, Faculty of Medicine and 
      Health Sciences , Universiti Putra Malaysia , Serdang , Selangor , Malaysia.
FAU - Ho, Gwo Fuang
AU  - Ho GF
AD  - b Clinical Oncology Unit , University Malaya Medical Centre , Kuala Lumpur , 
      Malaysia.
FAU - Annuar, Muhammad Azrif Bin Ahmad
AU  - Annuar MABA
AD  - c Radiotherapy & Oncology , Universiti Kebangsaan Malaysia Medical Centre, Jalan 
      Yaacob Latif, Bandar Tun Razak , Kuala Lumpur , Malaysia.
FAU - Stanslas, Johnson
AU  - Stanslas J
AD  - a Pharmacotherapeutics Unit, Department of Medicine, Faculty of Medicine and 
      Health Sciences , Universiti Putra Malaysia , Serdang , Selangor , Malaysia.
LA  - eng
PT  - Journal Article
DEP - 20170606
PL  - England
TA  - Biomarkers
JT  - Biomarkers : biochemical indicators of exposure, response, and susceptibility to 
      chemicals
JID - 9606000
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Orosomucoid)
RN  - 0 (Taxoids)
RN  - 15H5577CQD (Docetaxel)
SB  - IM
MH  - Antineoplastic Agents/adverse effects
MH  - Biomarkers/*blood
MH  - Breast Neoplasms/*drug therapy
MH  - China/ethnology
MH  - Docetaxel
MH  - Drug-Related Side Effects and Adverse Reactions/blood/diagnosis
MH  - Exanthema/blood/chemically induced/diagnosis
MH  - Female
MH  - Humans
MH  - India/ethnology
MH  - Malaysia
MH  - Orosomucoid/*analysis
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Stomatitis/blood/chemically induced/diagnosis
MH  - Taxoids/*adverse effects
OTO - NOTNLM
OT  - AAG
OT  - adverse events
OT  - docetaxel
OT  - oral mucositis
OT  - rash
EDAT- 2017/05/31 06:00
MHDA- 2018/08/21 06:00
CRDT- 2017/05/31 06:00
PHST- 2017/05/31 06:00 [pubmed]
PHST- 2018/08/21 06:00 [medline]
PHST- 2017/05/31 06:00 [entrez]
AID - 10.1080/1354750X.2017.1334152 [doi]
PST - ppublish
SO  - Biomarkers. 2018 Mar;23(2):142-146. doi: 10.1080/1354750X.2017.1334152. Epub 2017 
      Jun 6.